Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine

Information

  • Patent Grant
  • 10035786
  • Patent Number
    10,035,786
  • Date Filed
    Monday, October 9, 2017
    7 years ago
  • Date Issued
    Tuesday, July 31, 2018
    6 years ago
Abstract
3-(3-Chloro-1H-pyrazol-1-yl)pyridine is prepared by cyclizing 3-hydrazinopyridine.dihydrochloride with commercially available 3-ethoxyacrylonitrile to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine, and by converting the amino group to a chloro group by a Sandmeyer reaction.
Description
BACKGROUND

The present invention concerns an improved process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine.


US 20130288893(A1) describes, inter alia, certain (3-halo-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amides and carbamates and their use as pesticides. The route to prepare such compounds involved the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) by the direct coupling of 3-bromopyridine with 3-chloropyrazole. The 3-chloropyrazole was prepared by a) treating 1H-pyrazole with 2-dimethylsulfamoyl chloride and sodium hydride to provide N,N-dimethyl-1H-pyrazole-1-sulfonamide, b) treating the N,N-dimethyl-1H-pyrazole-1-sulfonamide with perchloroethane and n-butyl lithium to provide 3-chloro-N,N-dimethyl-1H-pyrazole-1-sulfonamide, and c) removing the N,N-dimethylsulfonamide from 3-chloro-N,N-dimethyl-1H-pyrazole-1-sulfonamide with trifluoroacetic acid to give the 3-chloropyrazole.


The disclosed process produces low yields, relies on a starting material that is difficult to prepare (3-chloropyrazole) and provides a product that is difficult to isolate in a pure form. It would be desirable to have a process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine that avoids these problems.


SUMMARY

The present invention provides such an alternative by cyclizing 3-hydrazinopyridine-dihydrochloride with commercially available 3-ethoxyacrylonitrile to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a), and by converting the amino group to a chloro group by a Sandmeyer reaction. Thus, the present invention concerns a process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b),




embedded image



which comprises


a) treating 3-hydrazinopyridine-dihydrochloride




embedded image



with 3-ethoxyacrylonitrile




embedded image



in a (C1-C4) aliphatic alcohol at a temperature of about 25° C. to about 100° C. in the presence of an alkali metal (C1-C4) alkoxide to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a)




embedded image


b) treating the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) in aqueous hydrochloric acid with sodium nitrite at a temperature of about 0° C. to about 25° C. to provide the diazonium salt (8b)




embedded image



and


c) treating the diazonium salt (8b) with copper chloride at a temperature of about 0° C. to about 25° C.







DETAILED DESCRIPTION

The present invention provides an improved process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) by cyclizing 3-hydrazinopyridine.dihydrochloride with commercially available 3-ethoxyacrylonitrile to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a), and by converting the amino group to a chloro group by a Sandmeyer reaction.


In the first step, 3-hydrazinopyridine.dihydrochloride is treated with 3-ethoxyacrylonitrile in a (C1-C4) aliphatic alcohol at a temperature of about 25° C. to about 100° C. in the presence of an alkali metal (C1-C4) alkoxide to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a). While stoichiometric amounts of 3-hydrazinopyridine.dihydrochloride and 3-ethoxyacrylonitrile are required, it is often convenient to use about a 1.5 fold to about a 2 fold excess of 3-ethoxy-acrylonitrile. The cyclization is run in the presence of an alkali metal (C1-C4) alkoxide base. It is often convenient to use about a 2 to about a 5 fold excess of base. The cyclization is performed in a (C1-C4) aliphatic alcohol. It is most convenient that the alkoxide base and the alcohol solvent be the same, for example, sodium ethoxide in ethanol. It is appreciated that methoxyacrylonitrile and propoxyacrylonitrile would be suitable for effecting this cyclization.


In a typical reaction, 3-hydrazinopyridine.dihydrochloride and an anhydrous alcohol are introduced into a reaction vessel and the alkoxide base is gradually added. The mixture is stirred and the 3-ethoxyacrylonitrile is added. The mixture is stirred at about 80° C. until most of the 3-hydrazinopyridine has reacted. The mixture is allowed to cool and the excess base is neutralized with acid. The crude 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) is conveniently isolated and purified by standard techniques.


The 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) is then converted to the desired 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) by treatment in aqueous hydrochloric acid with sodium nitrite at a temperature of about 0° C. to about 25° C. to provide a diazonium salt followed by treatment of the diazonium salt with copper chloride at a temperature of about 0° C. to about 25° C. While stoichiometric amounts of reagents are required, it is often convenient to use an excess of reagents with respect to the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a). Thus, aqueous hydrochloric acid is used in large excess as the reaction medium. Sodium nitrite is used in about a 1.3 fold to about a 2 fold excess. Copper chloride is used in about 5 mole percent to about 60 mole percent excess, preferably from about 15 mole percent to about 30 mole percent excess. The copper chloride may be either copper(I) chloride or copper(II) chloride. To suppress foaming during the reaction a water-immiscible organic solvent such as toluene or chloroform can be added during the treatment of the diazonium salt with copper chloride.


In a typical reaction, a mixture of 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) and aqueous hydrochloric acid are mixed and cooled to about 0° C. An aqueous solution of sodium nitrite is slowly added maintaining the temperature below about 5° C. The suspension is stirred at about 0° C. for about 2 hours. In a separate vessel, a mixture of copper(I) chloride and toluene is cooled to about 0° C. and the chilled suspension of diazonium salt is added at a rate maintaining the temperature below about 5° C. The mixture is allowed to warm to about ambient temperature. After completion of the reaction, the mixture is treated with aqueous sodium hydroxide to adjust the pH to about 8 to about 10. The resulting solution is extracted with a water-immiscible organic solvent. After removal of the solvent, the 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) can be used directly in the next step or further purified by standard techniques such as flash column chromatography or crystallization.


The following examples are presented to illustrate the invention.


Examples
1. Preparation of 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a)



embedded image


To a three-neck round bottomed flask (50 mL) equipped with a reflux condenser was introduced 3-hydrazinopyridine.dihydrochloride (1.82 g, 10.0 mmol) and anhydrous ethanol (10.0 mL). Sodium ethoxide (21 wt % in EtOH, 11.8 mL, 31.5 mmol) was added over 5 minutes and the internal temperature increased from 23° C. to 30° C. The resultant light brown slurry turned light pink after stirring for 10 minutes. 3-Ethoxyacrylonitrile (2.06 mL, 20.0 mmol) was added over 5 minutes and the internal temperature remained at 30° C. The yellow mixture was stirred at 78° C. under nitrogen for 5 hours and was then cooled to 15° C. Hydrochloric acid (4 M in 1,4-dioxane, 2.90 mL) was added slowly to quench any excess base forming a light brown suspension. The mixture was concentrated under reduced pressure to afford a brown solid. The solid was partitioned in water (30 mL) and ethyl acetate (50 mL). The insoluble light brown solid was collected by filtration to afford the first portion of product (0.340 g, >95% pure by NMR). The aqueous layer was extracted with ethyl acetate (3×50 mL). The combined organic extracts were concentrated to afford dark brown wet solid. The mixture was suspended in ethyl acetate (10 mL), filtered, and washed with heptane (20 mL) to afford the second portion of product as a brown solid (1.00 g, >95% pure by 1H NMR). The title compound was obtained as a brown solid (1.34 g, 84%): 1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J=2.4 Hz, 1H), 8.33 (dd, J=4.8, 1.2 Hz, 1H), 8.23 (d, J=2.4 Hz, 1H), 8.01 (ddd, J=8.4, 2.8, 1.2 Hz, 1H), 7.42 (dd, J=8.4, 4.8 Hz, 1H), 5.80 (d, J=2.4 Hz, 1H), 5.19 (bs, 2H, —NH2); 13C NMR (100 MHz, DMSO-d6) δ 157.7, 144.7, 138.0, 136.2, 128.3, 123.9, 123.2, 97.1; EIMS m/z 160 ([M]+); HPLC (Zorbax SB-C8 column, P/N: 863954-306; mobile phase: A=water (0.1% formic acid), B=acetonitrile (0.01% formic acid); Gradient from 5 to 100% acetonitrile over 15 minutes; flow: 1.0 mL/minute): tR=1.95 minutes.


2. Preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b)



embedded image


To a three-neck round bottomed flask (25 mL) was introduced 3-amino-1-(3-pyridyl)-pyrazole (0.480 g, 3.00 mmol) and concentrated hydrochloric acid (4.6 mL). The vigorously stirred mixture was cooled to −5° C. using a sodium chloride ice-bath. Sodium nitrite (0.269 g, 3.90 mmol) in water (1.3 mL) was added dropwise over 40 minutes while maintaining the temperature at −5° C. The resultant dark orange mixture was stirred for 1 hour between −5° C. and −0° C. and then added dropwise into a suspension of copper(I) chloride (0.475 g, 4.80 mmol) in chloroform (4.8 mL) at 25° C. over 15 minutes. The dark green slurry was stirred at room temperature for 1 hour. Water (10 mL) and chloroform (10 mL) was added to the mixture leading to a dark green solution. The acidic aqueous solution was neutralized by sodium hydroxide (50% in water) to pH 8 and extracted with chloroform (2×10 mL) and ethyl acetate (3×20 mL). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude product as a yellow solid (0.476 g). LC assay using di-n-propyl phthalate as internal standard indicated 73.7% purity (0.351 g, 65%): 1H NMR (400 MHz, CDCl3) δ 8.94 (d, J=2.8 Hz, 1H), 8.57 (dd, J=4.8, 1.2 Hz, 1H), 8.03 (ddd, J=8.4, 2.8, 1.6 Hz, 1H), 7.90 (d, J=2.4 Hz, 1H), 7.41 (ddd, J=8.4, 4.8, 0.8 Hz, 1H), 6.45 (d, J=2.4 Hz, 1H); EIMS m/z 179 ([M]+); HPLC (Zorbax SB-C8 column, P/N: 863954-306; mobile phase: A=water (0.1% formic acid), B=acetonitrile (0.01% formic acid); Gradient from 5 to 100% acetonitrile over 15 minutes; flow: 1.0 mL/minute): tR=6.28 minutes.

Claims
  • 1. A process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b),
  • 2. The process of claim 1, wherein the copper chloride is in about 15 mole percent to about 30 mole percent excess.
  • 3. The process of claim 1, wherein the copper chloride is copper (I) chloride.
  • 4. The process of claim 1, wherein the copper chloride is copper (II) chloride.
  • 5. The process of claim 1, further comprising adding a water immiscible organic solvent to suppress foaming.
  • 6. The process of claim 5, wherein the water immiscible organic solvent is toluene or chloroform.
  • 7. The process of claim 5, further comprising adding aqueous sodium hydroxide until a pH of about 8 to about 10 is achieved.
  • 8. The process of claim 1, wherein the copper chloride is mixed with toluene prior to the step of treating.
  • 9. The process of claim 8, wherein the copper chloride is mixed with toluene and cooled to a temperature of about 0° C. prior to the step of treating.
  • 10. The process of claim 1, wherein the diazonium salt (8b) is in an aqueous suspension.
  • 11. The process of claim 10, wherein the aqueous suspension is cooled to about 0° C. prior to the step of treating.
  • 12. The process of claim 1, wherein the treating comprises contacting a mixture of the copper chloride in toluene with an aqueous suspension of the diazonium salt (8b).
  • 13. The process of claim 12, wherein the mixture of the copper chloride in toluene is cooled to a temperature of about 0° C. prior to the step of treating.
  • 14. The process of claim 12, wherein the aqueous suspension of the diazonium salt (8b) is cooled to about 0° C. prior to the step of treating.
  • 15. The process of claim 13, wherein the aqueous suspension of the diazonium salt (8b) is cooled to about 0° C. prior to the step of treating.
  • 16. The process of claim 15, wherein the aqueous suspension of the diazonium salt (8b) is added to the mixture of the copper chloride in toluene.
  • 17. The process of claim 16, wherein the aqueous suspension of the diazonium salt (8b) is added to the mixture of the copper chloride in toluene at a rate maintaining the temperature below about 5° C.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 15/389,531 filed on Dec. 23, 2016, which is a divisional of U.S. application Ser. No. 14/988,773 filed on Jan. 6, 2016, which is a continuation of U.S. application Ser. No. 14/666,814 filed on Mar. 24, 2015, which is a continuation of U.S. application Ser. No. 14/517,349 filed on Oct. 17, 2014, which claims the benefit of U.S. Provisional Patent Application Ser. No. 62/031,533, filed Jul. 31, 2014, the entire disclosures of which are hereby expressly incorporated by reference in this Application.

US Referenced Citations (151)
Number Name Date Kind
3597341 Oswald Aug 1971 A
4080457 Harrison et al. Mar 1978 A
4260765 Harrison et al. Apr 1981 A
4407803 Haviv et al. Oct 1983 A
4536506 Marcoux et al. Aug 1985 A
4556671 Copp et al. Dec 1985 A
4734125 Gehring et al. Mar 1988 A
4810719 Appleton et al. Mar 1989 A
4824953 Bronn Apr 1989 A
5220028 Iwasawa et al. Jun 1993 A
5625074 Daum et al. Apr 1997 A
5631380 Haas et al. May 1997 A
5652372 Muller et al. Jul 1997 A
5693657 Lee et al. Dec 1997 A
5750718 Muller et al. May 1998 A
5817677 Linz et al. Oct 1998 A
5854264 Anthony et al. Dec 1998 A
5854265 Anthony et al. Dec 1998 A
5869681 Muller et al. Feb 1999 A
6040331 Yamamoto et al. Mar 2000 A
6218418 Pevarello et al. Apr 2001 B1
6413984 Philippo et al. Jul 2002 B1
6506747 Betageri et al. Jan 2003 B1
6548525 Galemmo, Jr. et al. Apr 2003 B2
6720427 Sanner et al. Apr 2004 B2
6878196 Harada et al. Apr 2005 B2
6916927 Bunnage et al. Jul 2005 B2
6965032 Freudenberger et al. Nov 2005 B2
7192906 Hirohara et al. Mar 2007 B2
7196104 Askew, Jr. et al. Mar 2007 B2
7319108 Scwink et al. Jan 2008 B2
7774978 Ding et al. Aug 2010 B2
7803832 Critcher et al. Sep 2010 B2
7910606 Nazere et al. Mar 2011 B2
7923573 Tamaki et al. Apr 2011 B2
8163756 Flynn et al. Apr 2012 B2
8222280 Liu et al. Jul 2012 B2
8901153 Buysse et al. Dec 2014 B2
9024031 Yang et al. May 2015 B1
9029554 Yang et al. May 2015 B1
9029555 Li et al. May 2015 B1
9029556 Yang et al. May 2015 B1
9044017 Yang et al. Jun 2015 B2
9085552 Li et al. Jul 2015 B1
9085564 Yang et al. Jul 2015 B2
9102654 Yang et al. Aug 2015 B2
9102655 Yang et al. Aug 2015 B2
9108932 Ross et al. Aug 2015 B2
9108946 Yang et al. Aug 2015 B2
9115115 Yang et al. Aug 2015 B1
9126974 Yang et al. Sep 2015 B2
9156813 Li et al. Oct 2015 B1
9174962 Yang et al. Nov 2015 B2
9199942 Yang et al. Dec 2015 B2
9199964 Yang et al. Dec 2015 B1
9249122 Yang et al. Feb 2016 B1
9255081 Li et al. Feb 2016 B1
9255082 Yang et al. Feb 2016 B2
9255083 Yang et al. Feb 2016 B2
9260396 Yang et al. Feb 2016 B2
9371310 Yang et al. Jun 2016 B2
9414594 Yang et al. Aug 2016 B2
9422265 Li et al. Aug 2016 B2
9433215 Yang et al. Sep 2016 B2
9434712 Yang et al. Sep 2016 B2
9447048 Yang et al. Sep 2016 B2
9522900 Yang et al. Dec 2016 B2
9540342 Yang et al. Jan 2017 B2
9550751 Yang et al. Jan 2017 B2
9573931 Yang et al. Feb 2017 B2
9580403 Li et al. Feb 2017 B2
9580405 Yang et al. Feb 2017 B2
9604942 Ross et al. Mar 2017 B2
9611247 Yang et al. Apr 2017 B2
9661849 Yang et al. May 2017 B2
9663489 Li et al. May 2017 B2
9670164 Yang et al. Jun 2017 B2
9670178 Yang et al. Jun 2017 B2
9723839 Yang et al. Aug 2017 B2
9796682 Yang et al. Oct 2017 B2
20020013326 Tiebes et al. Jan 2002 A1
20030153464 Nakamura et al. Aug 2003 A1
20030213405 Harada et al. Nov 2003 A1
20040043904 Yamaguchi et al. Mar 2004 A1
20040082629 Iwataki et al. Apr 2004 A1
20050038059 Mueller et al. Feb 2005 A1
20050176710 Schwink et al. Aug 2005 A1
20060135778 Schnatterer et al. Jun 2006 A1
20060160857 Buettelmann et al. Jul 2006 A1
20060160875 Gaines et al. Jul 2006 A1
20060167020 Dickerson et al. Jul 2006 A1
20060287365 Billen et al. Dec 2006 A1
20060287541 Nishino et al. Dec 2006 A1
20070049604 Nam et al. Mar 2007 A1
20070167426 Siddiqui et al. Jul 2007 A1
20080004301 Tamaki et al. Jan 2008 A1
20080027046 Annan et al. Jan 2008 A1
20090023709 Gillespie et al. Jan 2009 A1
20090069288 Breinlinger et al. Mar 2009 A1
20090137524 Billen et al. May 2009 A1
20090275592 Zeng et al. Nov 2009 A1
20090325956 Taniguchi et al. Dec 2009 A1
20100130474 Bothmann et al. May 2010 A1
20100204164 Crouse et al. Aug 2010 A1
20100286169 Guiles et al. Nov 2010 A1
20100292253 Trullinger et al. Nov 2010 A1
20100305200 Velicelebi et al. Dec 2010 A1
20110021771 Mallais et al. Jan 2011 A1
20110048261 Shimura Mar 2011 A1
20110098287 Bretschneider et al. Apr 2011 A1
20110118290 Bretschneider et al. May 2011 A1
20110166129 Machacek et al. Jul 2011 A1
20110166143 Bretschneider et al. Jul 2011 A1
20110184188 Wada et al. Jul 2011 A1
20110201649 Matsuzaki et al. Aug 2011 A1
20110212949 Bretschneider et al. Sep 2011 A1
20110275583 Bretschneider et al. Nov 2011 A1
20110319428 Fuβlein et al. Dec 2011 A1
20120053146 Parker et al. Mar 2012 A1
20120094837 Muhlthau et al. Apr 2012 A1
20120095023 Bretschneider et al. Apr 2012 A1
20120101294 Hirota et al. Apr 2012 A1
20120110701 Garizi et al. May 2012 A1
20120110702 Yap et al. May 2012 A1
20120115811 Du et al. May 2012 A1
20120165345 Bretschneider et al. Jun 2012 A1
20120172218 Crouse et al. Jul 2012 A1
20120220453 Lowe et al. Aug 2012 A1
20120252770 Berger et al. Oct 2012 A1
20130019348 Crouse et al. Jan 2013 A1
20130072382 Trullinger et al. Mar 2013 A1
20130089622 Trullinger et al. Apr 2013 A1
20130109566 Niyaz et al. May 2013 A1
20130261141 Bretschneider et al. Oct 2013 A1
20130288893 Buysse et al. Oct 2013 A1
20130291227 Buysse et al. Oct 2013 A1
20130324736 Ross, Jr. et al. Dec 2013 A1
20130324737 Ross, Jr. et al. Dec 2013 A1
20130338367 Numata et al. Dec 2013 A1
20140162874 Yap et al. Jun 2014 A1
20150112076 Yang et al. Apr 2015 A1
20150252016 Yang et al. Sep 2015 A1
20160152593 Li et al. Jun 2016 A1
20170044134 Yang et al. Feb 2017 A1
20170081288 Yang et al. Mar 2017 A1
20170101392 Yang et al. Apr 2017 A1
20170101393 Li et al. Apr 2017 A1
20170215420 Yang et al. Aug 2017 A1
20170217924 Li et al. Aug 2017 A1
20170226078 Yang et al. Aug 2017 A1
20170233367 Yang et al. Aug 2017 A1
Foreign Referenced Citations (101)
Number Date Country
87107798 May 1988 CN
1339027 Mar 2002 CN
1373662 Oct 2002 CN
1852885 Oct 2006 CN
1307161 Mar 2007 CN
101228134 Jul 2008 CN
0097323 Jan 1984 EP
0190457 Aug 1986 EP
0205024 Dec 1986 EP
0232538 Aug 1987 EP
0248315 Dec 1987 EP
0425948 May 1991 EP
0273549 Jan 1992 EP
1273582 Jan 2003 EP
1321463 Jun 2003 EP
1329160 Jul 2003 EP
1757590 Feb 2007 EP
1987-153273 Jul 1987 JP
1988-174905 Jul 1988 JP
1989-226815 Sep 1989 JP
2003-212864 Jul 2003 JP
2004-051628 Feb 2004 JP
2004-292703 Oct 2004 JP
2012-188418 Oct 2012 JP
2013-075871 Apr 2013 JP
2013-082699 May 2013 JP
2013-082704 May 2013 JP
2013-107867 Jun 2013 JP
2013-129651 Jul 2013 JP
2013-129653 Jul 2013 JP
1994013644 Jun 1994 WO
1997036897 Oct 1997 WO
1998049166 Nov 1998 WO
2000035919 Jun 2000 WO
200112189 Feb 2001 WO
2001034127 May 2001 WO
2001090078 Nov 2001 WO
2002083111 Oct 2002 WO
2003008405 Jan 2003 WO
2003072102 Sep 2003 WO
2004041813 May 2004 WO
2005070925 Aug 2005 WO
2005074875 Aug 2005 WO
2006023462 Mar 2006 WO
2006033005 Mar 2006 WO
2006046593 May 2006 WO
2006103045 Oct 2006 WO
2007005838 Jan 2007 WO
2008090382 Jul 2007 WO
2007087427 Aug 2007 WO
2007098826 Sep 2007 WO
2008005457 Jan 2008 WO
2008079277 Jul 2008 WO
2009149858 Dec 2009 WO
2010006713 Jan 2010 WO
2010009290 Jan 2010 WO
2010012442 Feb 2010 WO
2010033360 Mar 2010 WO
2010048207 Apr 2010 WO
2010060379 Jun 2010 WO
2010075376 Jul 2010 WO
2010129497 Nov 2010 WO
2010133336 Nov 2010 WO
2010146236 Dec 2010 WO
2011003065 Jan 2011 WO
2011043371 Apr 2011 WO
2011045224 Apr 2011 WO
2011045240 Apr 2011 WO
2011091153 Jul 2011 WO
2011101229 Aug 2011 WO
2011126903 Oct 2011 WO
2011128304 Oct 2011 WO
2011134964 Nov 2011 WO
2011138285 Nov 2011 WO
2011163518 Dec 2011 WO
2012000896 Jan 2012 WO
2012004217 Jan 2012 WO
2012007500 Jan 2012 WO
2010035011 Mar 2012 WO
2012052412 Apr 2012 WO
2012061290 May 2012 WO
2012070114 May 2012 WO
2012102387 Aug 2012 WO
2012108511 Aug 2012 WO
2012147107 Nov 2012 WO
2012168361 Dec 2012 WO
2013000931 Jan 2013 WO
2013010946 Jan 2013 WO
2013010947 Jan 2013 WO
2013062980 May 2013 WO
2013062981 May 2013 WO
2013064324 May 2013 WO
2013156431 Oct 2013 WO
2013156433 Oct 2013 WO
2013162716 Oct 2013 WO
2015058020 Apr 2015 WO
2015058022 Apr 2015 WO
2015058023 Apr 2015 WO
2015058024 Apr 2015 WO
2015058026 Apr 2015 WO
2015058028 Apr 2015 WO
Non-Patent Literature Citations (25)
Entry
Kempe et al., “Responsive Glyco-poly(2-oxaoline)s: Synthesis, Cloud Point Tuning, and Lectin Binding,” Biomacromolecules 2011, vol. 12, pp. 2591-2600.
Fields et al., “Preparation of Trifluoromethyl-Pyrazoles and-Pyrazolines by the Reaction of 2,2,2-Trifluorodiazoethane with Carbon-Carbon Multiple Bonds,” Journal of Fluorine Chemistry, 1979, vol. 13, pp. 147-158.
Bradbury et al., “Enzyme-catalysed peptide amidation,” Eur. J. Biochem. 1987, vol. 169, pp. 579-584.
International Search Report and Written Opinion for PCT/US2014/061005 dated Dec. 16, 2014.
International Search Report and Written Opinion for PCT/US2014/061006 dated Dec. 8, 2014.
International Search Report and Written Opinion for PCT/US2014/061007 dated Dec. 31, 2014.
International Search Report and Written Opinion for PCT/US2014/061009 dated Dec. 8, 2014.
International Search Report and Written Opinion for PCT/US2014/061010 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061012 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061014 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061016 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061022 dated Dec. 29, 2014.
International Search Report and Written Opinion for PCT/US2014/061023 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061024 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061027 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061029 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061030 dated Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2013/029615 dated May 8, 2013.
Ameduri, B. et al., “Synthesis and polymerization of fluorinated monomers bearing a reactive lateral group Part 4. Preparation of functional perfluorovinyl monomers by radical addition of functional mercaptans to 1,1,2-trifluoro-1,4-pentadiene.” J. Fluorine Chemistry, 92, 77-84 (1998).
International Preliminary Report on Patentability for PCT/US2011/058578 dated Dec. 21, 2012.
International Search Report and Written Opinion for PCT/US2011/058578 dated Apr. 5, 2012.
Kadam, S.S. et al., “Synthesis and Tautomerism of Substituted Pyrazolo[4,3-c]pyrazoles.” Eur. J. Chem., 6811-6822 (2013).
National Center for Biotechnology Information, PubChem Compound Database; CID=17132489,https://pubchem.ncbi.nlm.nih.gov/compound/17132489, create date Nov. 13, 2007.
Frigola; European Journal of Medicinal Chemistry 1989, 435-445.
Binz et al. “Derivatives of pyridine, etc.,” CA 25:30083 (1931).
Related Publications (1)
Number Date Country
20180030029 A1 Feb 2018 US
Provisional Applications (1)
Number Date Country
62031533 Jul 2014 US
Divisions (2)
Number Date Country
Parent 15389531 Dec 2016 US
Child 15727718 US
Parent 14988773 Jan 2016 US
Child 15389531 US
Continuations (2)
Number Date Country
Parent 14666814 Mar 2015 US
Child 14988773 US
Parent 14517349 Oct 2014 US
Child 14666814 US